6-K 1 tm2426724d2_6k.htm FORM 6-K

 

 

 

美國

證券交易委員會

華盛頓特區20549

 

 

 

表格6-K

 

 

 

外國私人發行人之報告

根據13a-16或15d-16規則

根據1934年證券交易所法

 

2024年十月份

 

委員會文件編號: 001-36515

 

 

 

Materialise NV

 

 

 

技術支援 15

3001 魯汶

比利時

(總部辦公地址)

 

 

 

請用勾選標記表示,登記申報人是否會以20-F表格或40-F表格提交或將要提交年度報告。

 

Form 20-Fx            40-F申報表  ¨

 

此6-k表格已納入提交者在F-3表格登記申報書中(檔案號碼333-213649)的參考。

 

 

 

 

 

 

2024年第三季度財務結果

 

除非根據上下文另有要求,否則“materialise”、“公司”、“我們”及“我們的”指的是Materialise NV及其子公司。

 

2024年第三季度成果

 

2024年第三季度的總營業收入增加了14.2%,從2023年第三季度的60,130千歐元增至68,652千歐元。

 

我們的materialise醫療業務營業收入在2024年第三季增加了24.5%,至30,197 kEUR,相較於2023年同期的24,263 kEUR。

 

我們的materialise軟體部門營業收入於2024年第三季增加了2.8%,達到11,111千歐元,相較於去年同季的10,811千歐元。

 

我們materialise製造業部門的營業收入在2024年第三季較2013年同期的25056千歐元增加了9.1%,達到27344千歐元。

 

毛利潤為39,297 kEUR,較去年同期的33,696 kEUR高,而毛利潤佔營業收入百分比也從2023年第三季的56.0%增加到57.2%。

 

研究和開發("R&D")、銷售和行銷("S&M")、以及一般行政("G&A")支出總體上從2023年第三季的32,076 kEUR增加了11.8%,達到了2024年第三季的35,856 kEUR。

 

淨其他營業收入從2023年第三季的710千歐元增至872千歐元。

 

營運業績達到4,313千歐元,較2023年第三季的2,330千歐元有所增加。

 

淨財務結果為(1,137) 千歐元,相較於2023年第三季的1,319千歐元,反映了不利貨幣兌換效應的影響。

 

2024年第三季度所得稅結果為(138)千歐元,較2023年第三季度的363千歐元低。

 

由於上述原因,2024年第三季的凈利潤為3,038 kEUR,較2023年同期的4,013 kEUR低。2024年第三季的綜合收益總額,包括外國業務翻譯的匯兌損益,在這一期間為3,777 kEUR,而對應的2023年期間為3,242 kEUR。

 

截至2024年9月30日,我們的現金及現金等價物為116,163千歐元,相較於2023年12月31日的127,573千歐元。總負債金額為53,037千歐元,相較於2023年12月31日的64,398千歐元。因此,我們的淨現金狀況(扣除總負債的現金及現金等價物)為63,126千歐元,相較於2023年12月31日的63,175千歐元。

 

2024年第三季度營運活動的現金流量為6,870 kEUR,較2023年同期的8,143 kEUR低。2024年第三季度的總資本支出為7,328 kEUR。

 

2024年9月30日的凈股東權益為246,989千歐元,相較於2023年12月31日的236,594千歐元。

 

經調整後,2024年第三季度的調整EBIT增至4,408 kEUR,較2023年期間的2,330 kEUR增加。2024年第三季度的調整EBIT利潤率(調整EBIT除以總收入)為6.4%,較2023年第三季度的3.9%高。調整後的EBITDA於2024年第三季度增至9,895 kEUR,而2023年期間為7,857 kEUR。

 

 

 

 

我們的Materialise醫療部門調整後的EBITDA在2024年第三季度增加了38.5%,從7,143 kEUR增至9.895 kEUR,而該部門的調整後EBITDA利潤率(部門調整後EBITDA除以部門收入)為32.8%,而2023年第三季度則為29.4%。

 

我們的materialise軟體部門調整後的EBITDA從1,781 kEUR增加了10.9%至1,975 kEUR,而該部門的調整後EBITDA利潤率為17.8%,相較於對應的去年同期的16.5%。

 

我們的materialise製造業部門調整後EBITDA金額為701千歐元,較去年同期的1,074千歐元低,而該部門的調整後EBITDA利潤率為2.6%,低於2023年第三季的4.3%。

 

非國際財務報告標準措施

 

materialise將EBIt、EBITDA、調整後的EBIt和調整後的EBITDA作為其財務表現的補充性財務指標。EBIt的計算方法是凈利潤加上所得稅、財務費用(減去財務收入)和合資企業中的利潤或損失份額。EBITDA的計算方法是凈利潤加上所得稅、財務費用(減去財務收入)、合資企業中的利潤或損失份額以及折舊和攤銷。調整後的EBIt和調整後的EBITDA是通過將股份或股權報酬費用、與業務組合相關的併購費用、減值及因業務組合重新評價公允價值的金額分別加到EBIt和EBITDA中確定的。管理層認為這些非IFRS措施是重要的指標,因為它們排除了主要反映融資決策影響的項目,並且在EBITDA和調整後的EBITDA的情況下,主要反映了長期投資,而不是公司日常業務運營的表現。該公司還使用業務分部調整後的EBITDA來評估其三個業務分部的表現。與凈利潤相比,這些指標的局限在於它們沒有反映必要支付公司債務利息或本金的現金需求,而在EBITDA和調整後的EBITDA的情況下,這些指標進一步受到限制,因為它們沒有反映在公司業務中產生收入的部分資本化有形和無形資產的周期性費用,或與減損相關的變化。管理層通過其他財務指標,如財務費用、資本支出和營運活動現金流量,評估這些項目。該公司認為這些測量對衡量公司的增長能力或作為估值指標很有用。該公司計算的EBIt、EBITDA、調整後的EBIt和調整後的EBITDA可能無法與其他公司報告的同名指標相匹配。EBIt、EBITDA、調整後的EBIt和調整後的EBITDA不應被視為根據IFRS衍生的凈利潤或任何其他績效衡量指標的替代品。該公司對EBIt、EBITDA、調整後的EBIt和調整後的EBITDA的呈報不應被解釋為暗示其未來的結果不會受到飛凡或非遞延項目的影響。

 

匯率

 

本文件僅為方便讀者而將某些歐元金額按指定匯率換算為美元。除非另有說明,本文件中所有從歐元轉換為美元的金額均以1歐元兌換1.1196美元的匯率換算,該匯率為2024年9月30日歐洲央行的參考匯率。

 

About Materialise

 

Materialise incorporates over 30 years of 3D printing experience into a range of software solutions and 3D printing services, which form the backbone of the 3D printing industry. Materialise’s open and flexible solutions enable players in a wide variety of industries, including healthcare, automotive, aerospace, art and design, and consumer goods, to build innovative 3D printing applications that aim to make the world a better and healthier place. Headquartered in Belgium, with branches worldwide, Materialise combines one of the largest groups of software developers in the industry with one of the largest and most complete 3D printing facilities in the world.

 

 

 

 

Consolidated income statements (Unaudited)

 

   for the three months ended
September 30,
   for the nine months ended
September 30,
 
In '000  2024   2024   2023   2024   2023 
   U.S.$             
Revenue   76,862    68,652    60,130    201,085    190,832 
Cost of Sales   (32,866)   (29,355)   (26,435)   (86,625)   (83,249)
Gross Profit   43,997    39,297    33,696    114,461    107,583 
Gross profit as % of revenue   57.2%   57.2%   56.0%   56.9%   56.4%
                          
Research and development expenses   (12,292)   (10,979)   (9,476)   (32,301)   (27,982)
Sales and marketing expenses   (16,678)   (14,896)   (13,960)   (45,130)   (42,418)
General and administrative expenses   (11,175)   (9,981)   (8,640)   (29,195)   (27,213)
Net other operating income (expenses)   977    872    710    2,866    (3,238)
Operating (loss) profit   4,829    4,313    2,330    10,700    6,732 
                          
Financial expenses   (2,063)   (1,843)   (1,554)   (4,082)   (3,599)
Financial income   791    706    2,873    5,489    4,987 
(Loss) profit before taxes   3,557    3,176    3,649    12,106    8,120 
                          
Income Taxes   (154)   (138)   363    (1,607)   (886)
Net (loss) profit for the period   3,403    3,038    4,013    10,500    7,234 
Net (loss) profit attributable to:                         
The owners of the parent   3,409    3,045    4,017    10,520    7,251 
Non-controlling interest   (8)   (7)   (5)   (20)   (17)
                          
Earning per share attributable to owners of the parent                         
Basic   0.06    0.05    0.07    0.18    0.12 
Diluted   0.06    0.05    0.07    0.18    0.12 
                          
Weighted average basic shares outstanding   59,067    59,067    59,067    59,067    59,067 
Weighted average diluted shares outstanding   59,067    59,067    59,068    59,067    59,070 

 

 

 

 

Consolidated statements of comprehensive income (Unaudited)

 

   for the three months ended
September 30,
   for the nine months ended
September 30,
 
In 000€  2024   2024   2023   2024   2023 
   U.S.$             
Net profit (loss) for the period   3,403    3,038    4,013    10,500    7,234 
Other comprehensive income                         
Recycling                         
Exchange difference on translation of foreign operations   827    739    (770)   (317)   471 
Other comprehensive income (loss), net of taxes   827    739    (770)   (317)   471 
Total comprehensive income (loss) for the year, net of taxes   4,229    3,777    3,242    10,183    7,705 
Total comprehensive income (loss) attributable to:                         
The owners of the parent   4,237    3,785    3,248    10,204    7,721 
Non-controlling interests   (8)   (7)   (5)   (21)   (15)

 

 

 

 

Consolidated statement of financial position (Unaudited)

 

   As of
September 30,
   As of
December 31,
 
In 000€  2024   2023 
Assets          
Non-current assets          
Goodwill   43,355    43,158 
Intangible assets   30,987    31,464 
Property, plant & equipment   104,856    95,400 
Right-of-Use assets   7,889    8,102 
Deferred tax assets   2,673    2,797 
Investments in convertible loans   3,931    3,744 
Other non-current assets   5,829    5,501 
Total non-current assets   199,520    190,166 
Current assets          
Inventories   17,400    17,034 
Trade receivables   49,761    52,698 
Other current assets   11,814    9,161 
Cash and cash equivalents   116,163    127,573 
Total current assets   195,138    206,465 
Total assets   394,658    396,630 

 

 

 

 

   As of
September 30,
   As of
December 31,
 
In 000€  2024   2023 
Equity and liabilities          
Equity          
Share capital   4,487    4,487 
Share premium   234,155    233,942 
Retained earnings and other reserves   8,419    (1,783)
Equity attributable to the owners of the parent   247,061    236,646 
Non-controlling interest   (72)   (53)
Total equity   246,989    236,594 
Non-current liabilities          
Loans & borrowings   23,880    33,582 
Lease liabilities   5,403    5,333 
Deferred tax liabilities   3,324    3,725 
Deferred income   6,528    10,701 
Other non-current liabilities   697    1,745 
Total non-current liabilities   39,832    55,086 
Current liabilities          
Loans & borrowings   21,294    22,873 
Lease liabilities   2,460    2,610 
Trade payables   21,225    21,196 
Tax payables   2,924    1,777 
Deferred income   40,878    40,791 
Other current liabilities   19,056    15,703 
Total current liabilities   107,837    104,950 
Total equity and liabilities   394,658    396,630 

 

 

 

 

Consolidated statement of cash flows (Unaudited)

 

   for the nine months ended
September 30,
 
In 000€  2024   2023 
Operating activities          
Net (loss) profit for the period   10,500    7,234 
Non-cash and operational adjustments   16,964    15,136 
Depreciation of property plant & equipment   11,370    11,162 
Amortization of intangible assets   4,838    5,046 
Share-based payment expense   213    - 
Loss (gain) on disposal of intangible assets and property, plant & equipment   (114)   (401)
Movement in provisions   311    (434)
Movement reserve for bad debt and slow moving inventory   202    445 
Financial income   (5,492)   (4,811)
Financial expense   4,066    3,389 
Impact of foreign currencies   (15)   (152)
(Deferred) income taxes   1,584    892 
Working capital adjustments   (3,860)   (3,601)
Decrease (increase) in trade receivables and other receivables   1,666    8,965 
Decrease (increase) in inventories and contracts in progress   (672)   (751)
Increase (decrease) in deferred revenue   (4,284)   (4,532)
Increase (decrease) in trade payables and other payables   (569)   (7,283)
Income tax paid & Interest received   1,635    1,194 
Net cash flow from operating activities   25,239    19,963 

 

 

 

 

   for the nine months ended
September 30,
 
In 000€  2024   2023 
Investing activities          
Purchase of property, plant & equipment   (17,305)   (6,862)
Purchase of intangible assets   (1,312)   (2,448)
Proceeds from the sale of property, plant & equipment & intangible assets (net)   232    645 
Acquisition of subsidiary (net of cash)   (2,670)   - 
Net cash flow used in investing activities   (21,055)   (8,665)
Financing activities          
Repayment of loans & borrowings   (11,470)   (14,334)
Repayment of leases   (2,314)   (2,640)
Capital increase   -    - 
Interest paid   (1,052)   (1,334)
Other financial income (expense)   (240)   (25)
Net cash flow from (used in) financing activities   (15,077)   (18,334)
Net increase/(decrease) of cash & cash equivalents   (10,892)   (7,037)
Cash & Cash equivalents at the beginning of the year   127,573    140,867 
Exchange rate differences on cash & cash equivalents   (517)   123 
Cash & cash equivalents at end of the period   116,163    133,953 

 

 

 

 

Reconciliation of Net Profit (Loss) to EBITDA and Adjusted EBITDA (Unaudited)

 

   for the three months ended
September 30,
   for the nine months ended
September 30,
 
In 000€  2024   2023   2024   2023 
Net profit (loss) for the period   3,038    4,013    10,500    7,234 
Income taxes   138    (363)   1,607    886 
Financial expenses   1,843    1,554    4,082    3,599 
Financial income   (706)   (2,873)   (5,489)   (4,987)
Depreciation and amortization   5,487    5,527    16,241    16,191 
EBITDA   9,800    7,857    26,941    22,923 
Share-based compensation expense (1)   71    -    213    - 
Acquisition-related expenses of business combinations (2)   24    -    24    - 
Adjusted EBITDA   9,895    7,857    27,178    22,923 

           
(1) Share-based compensation expense represents the cost of equity-settled and share-based payments to employees.  
(2) Acquisition-related expenses of business combinations represent expenses incurred in connection with the acquisition of Feops.

 

Reconciliation of Net Profit (Loss) to EBIT and Adjusted EBIT (Unaudited)

 

   for the three months ended
September 30,
   for the nine months ended
September 30,
 
In 000€  2024   2023   2024   2023 
Net profit (loss) for the period   3,038    4,013    10,500    7,234 
Income taxes   138    (363)   1,607    886 
Financial expenses   1,843    1,554    4,082    3,599 
Financial income   (706)   (2,873)   (5,489)   (4,987)
EBIT   4,313    2,330    10,700    6,732 
Share-based compensation expense (1)   71    -    213    - 
Acquisition-related expenses of business combinations (2)   24    -    24    - 
Adjusted EBIT   4,408    2,330    10,937    6,732 

 

(1) Share-based compensation expense represents the cost of equity-settled and share-based payments to employees.

(2) Acquisition-related expenses of business combinations represent expenses incurred in connection with the acquisition of Feops.

 

 

 

 

Segment P&L (Unaudited)

 

In 000€  Materialise
Medical
   Materialise
Software
   Materialise
Manufacturing
   Total
segments
   Unallocated (1)   Consolidated 
For the three months ended September 30, 2024                              
Revenues   30,197    11,111    27,344    68,652    (0)   68,652 
Segment (adj) EBITDA   9,895    1,975    701    12,572    (2,677)   9,895 
Segment (adj) EBITDA %   32.8%   17.8%   2.6%   18.3%        14.4%
For the three months ended September 30, 2023                              
Revenues   24,263    10,811    25,056    60,130    0    60,130 
Segment (adj) EBITDA   7,143    1,781    1,074    9,998    (2,141)   7,857 
Segment (adj) EBITDA %   29.4%   16.5%   4.3%   16.6%        13.1%

 

In 000€  Materialise
Medical
   Materialise
Software
   Materialise
Manufacturing
   Total
segments
   Unallocated
(1)
   Consolidated 
For the nine months ended September 30, 2024                              
Revenues   84,522    32,775    83,789    201,085    0    201,085 
Segment (adj) EBITDA   26,015    4,439    4,648    35,103    (7,925)   27,178 
Segment (adj) EBITDA %   30.8%   13.5%   5.5%   17.5%        13.5%
For the nine months ended September 30, 2023                              
Revenues   73,528    33,192    84,112    190,832    0    190,833 
Segment (adj) EBITDA   17,179    6,190    6,980    30,349    (7,426)   22,923 
Segment (adj) EBITDA %   23.4%   18.7%   8.3%   15.9%        12.0%

 

(1)  Unallocated segment adjusted EBITDA consists of corporate research and development and corporate other operating income (expense), and the added share-based compensation expenses, acquisition related expenses of business combinations, impairments and fair value of business combinations that are included in Adjusted EBITDA.

 

 

 

 

Reconciliation of Net Profit (Loss) to Segment adjusted EBITDA (Unaudited)

 

   for the three months ended
September 30,
   for the nine months ended
September 30,
 
In 000€  2024   2023   2024   2023 
Net profit (loss) for the period   3,038    4,013    10,500    7,234 
Income taxes   138    (363)   1,607    886 
Financial cost   1,843    1,554    4,082    3,599 
Financial income   (706)   (2,873)   (5,489)   (4,987)
Operating (loss) profit   4,313    2,330    10,700    6,732 
Depreciation and amortization   5,487    5,527    16,241    16,191 
Corporate research and development   912    604    2,675    2,063 
Corporate headquarter costs   2,454    2,399    7,537    7,636 
Other operating income (expense)   (618)   (862)   (2,073)   (2,274)
Segment EBITDA adjustments (1)   24         24      
Segment adjusted EBITDA   12,572    9,998    35,103    30,349 

 

(1) Acquisition-related expenses of business combinations represent expenses incurred in connection with the acquisition of Feops.

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  MATERIALISE NV
     
  By: /s/ Brigitte de Vet-Veithen
  Name: Brigitte de Vet-Veithen
     
    De Vet Management BV
  Title: Chief Executive Officer

 

Date: October 24, 2024